Country Garden Venture Capital led a $66.3m series B2 round for the bioplastic and pathogen detector developer that included Septwolves Venture Capital.
Leyaoyao raised a nine-digit yuan amount from investors including 37 Interactive Entertainment while Lockheed Martin and Booz Allen Hamilton contributed to AI developer Latent AI's series A round.
Lilly Asia Ventures was among the participants in a series C round closed by the Ant Group and China Re-backed healthcare payment platform operator.
CRRC Times and Xiamen Xiangyu were among the LPs for the venture firm’s latest dollar vehicle that will invest in healtech companies concentrating on biotech, IVDs and medical supplies.
Alameda Research, Blockchain.com and Coinbase helped cryptocurrency exchange Pintu close a $35m round while small molecule drug developer Aardvark raised $29m.
The Adimab and GV-backed covid-19 antibody treatment developer has floated on Nasdaq at a $1.84bn valuation, about a year after it was founded.
Cigna Ventures returned to back an $83.5m round for the kidney care provider that also featured new investor Blue Shield of California.
The Angelini Lumira Biosciences Fund will invest in early-stage companies in Canada and the US.
JD Health has backed a $93m series D round for Rimag, while a couple of India-based startups delivered exits.
The China Union-backed drug contract manufacturer has raised the funding approximately a year and a half after a $60m series A.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
